US Merger & Acquisition SEC Filings — April 20, 2026

20-04-2026

Tigerless Health, Inc., a New York-based insurtech company, has entered a definitive business combination agreement with Piermont Valley Acquisition Corp. (PVAC), a SPAC, valuing Tigerless at an enterprise value of approximately $280 million, with the combined entity to be renamed Tigerless AI Holdings, Inc. and list on NASDAQ. Existing Tigerless shareholders will roll 100% of their equity, and the management team led by CEO Zikang Wu will continue post-closing. The transaction, unanimously approved by both boards, is expected to close in the second half of 2026, subject to regulatory approvals, stockholder votes, and customary conditions, with noted risks including potential delays or failure to close.

• ·Tigerless Health founded in 2018 and headquartered in New York City.
• ·PVAC completed initial public offering in December 2021.
• ·Legal representation: PVAC by Edelman Legal Consulting PLLC; Tigerless by Graubard Miller.
• ·Upcoming SEC filings: Registration Statement on Form S-4 serving as proxy statement.

20-04-2026

Range Capital Acquisition Corp., a Cayman Islands exempted company and SPAC, entered into a promissory note dated April 14, 2026, with Range Capital Holdings, LLC for principal up to $1,500,000, non-interest bearing, due on consummation of its initial business combination. The note may be prepaid at any time and, at the payee's option upon maturity, converted into Working Capital Units at $10.00 per unit, with terms matching those from the company's December 19, 2024 IPO private placement. No advances have been specified as outstanding in the filing.

• ·Note governed by Delaware law
• ·Conversion requires compliance with applicable securities laws; no fractional units issued
• ·Payee waives claims against the SPAC's IPO trust account
• ·IPO prospectus filed December 19, 2024

20-04-2026

Shareholders of TLGY Acquisition Corp approved special resolutions on April 15, 2026, amending Article 49.7 of the Amended and Restated Memorandum and Articles of Association to extend the deadline for consummating a business combination. The amendments introduce phased extensions (First to Fifth) up to multiple additional months, conditional on Sponsors or affiliates depositing monthly amounts into the Trust Account, ranging from the lesser of $0.04 per share or $200,000 down to $0.05 per share or $10,000. Without extension payments by the final deadline, the company will cease operations, redeem public shares, and liquidate.

• ·Extensions replace prior Article 49.7 text and allow pro rata deduction of unused prior extension payments from future ones.
• ·Board may deem resolution ineffective at its discretion within two business days of shareholder approval.
• ·Referenced prior extension deadlines: November 3, 2023 (First), May 16, 2024 (Second), April 16, 2026 (Third).

20-04-2026

AnaptysBio, Inc. (Nasdaq: ANAB) completed the taxable spin-off of its biopharma operations business, First Tracks Biotherapeutics, Inc., distributing one share of First Tracks common stock (Nasdaq: TRAX) for every share of Anaptys common stock owned as of the April 6, 2026 record date. Anaptys now operates as a virtual royalty management company exclusively handling financial collaborations for Jemperli royalties with GSK and imsidolimab with Vanda, featuring limited FTEs, minimal operating expenses, greater than 95% EBIT margin, and approximately $140-$145 million in net cash. This streamlined structure positions the company to protect and return royalty value to shareholders without operational complexity.

• ·Record date for spin-off distribution: April 6, 2026
• ·Anaptys continues trading on Nasdaq under 'ANAB'; First Tracks under 'TRAX' on Nasdaq Global Select Market

20-04-2026

First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) launched as an independent, publicly traded clinical-stage biotechnology company on April 20, 2026, following a spin-off from AnaptysBio, Inc., via a one-for-one share distribution to AnaptysBio shareholders of record on April 6, 2026. The company starts with $180 million in cash, providing a two-year cash runway, and a pipeline of three assets: ANB033 (Phase 1b for celiac disease and eosinophilic esophagitis), rosnilimab (completed Phase 2b for rheumatoid arthritis), and ANB101 (Phase 1a). No declines or flat metrics were reported.

• ·Spin-off record date: April 6, 2026
• ·Trading commenced on Nasdaq Global Select Market under ticker TRAX on April 20, 2026
• ·Investor contact: investors@firsttracksbio.com

20-04-2026

YHN Acquisition I Limited received two Nasdaq notification letters on April 17, 2026, for failing to comply with the minimum Market Value of Publicly Held Shares (MVPHS) requirement of $15,000,000 and the minimum Market Value of Listed Securities (MVLS) requirement of $50,000,000, each for 30 consecutive business days from March 5 to April 16, 2026. The company has 180 calendar days until October 14, 2026, to regain compliance by meeting the thresholds for at least 10 consecutive business days, with no immediate effect on trading of its Ordinary Shares (YHNA). Failure to comply could lead to delisting notices or a potential transfer to the Nasdaq Capital Market.

• ·Notifications received on April 17, 2026; filing dated April 20, 2026
• ·Compliance must be achieved for minimum of 10 consecutive business days prior to October 14, 2026
• ·Company classified as emerging growth company